(Q36533037)

14 August 2017

1 reference

title

Role of angiogenesis in chronic lymphocytic leukemia. (English)

1 reference

14 August 2017

0 references

5

Alessandra Ferrajoli

1 reference

14 August 2017

3

Srdan Verstovsek

1 reference

14 August 2017

2

Radovan Vrhovac

1 reference

14 August 2017

Tomislav Letilovic

1

1 reference

14 August 2017

Branimir Jaksic

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

107

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

925-934

1 reference

Tissue inhibitors of metalloproteinases: evolution, structure and function

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Overview of angiogenesis: Biologic implications for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Tumour angiogenesis and prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenesis induced by degradation products of hyaluronic acid.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Circulating endothelial cells in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Role of hematopoietic growth factors in angiogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

The thin red line: angiogenesis in normal and malignant hematopoiesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenesis is increased in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenesis in acute and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenin supports endothelial and fibroblast cell adhesion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

The angiogenic status of B-CLL B cells: role of the VEGF receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Cancer anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Inflammation and cancer: back to Virchow?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Angiogenesis in lymphoproliferative disorders: a therapeutic target?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22086

7 January 2021

Identifiers

DOI

10.1002/CNCR.22086

1 reference

14 August 2017

1 reference